Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

Exclusion Criteria

• •Prior facet related procedure (intraarticular corticosteroid injection, radiofrequency ablation (RFA)) in last 6 months or prior fusion in the bottom two facets.
• •Current opioid use of greater than 50mg oral morphine milligram equivalents per day.
• •No advanced imaging (MRI, CT or lumbar x-ray) of the lumbar spine within the last 6 months.
• •BMI \> 34.99 (WHO class I obesity).
• •Active systemic or local infection as evidenced by fever \>100.4 degrees Fahrenheit, or any other clinical signs or symptoms of infection within 24 hours of the procedure.
• •On anticoagulation drug and has been on hold for less than 7 days prior to the investigational procedure.
• •Imaging evidence of high likelihood of failure for intra-articular injection in the opinion of the PI or delegate review of MRI, CT or lumbar x-ray imaging.
• •History of chronic thrombocytopenia (or pre-operative platelet count less than 195,000 per μl).
• •Undergoing chemotherapy at time of injection.
• •Pregnant or breastfeeding.
• •Use of illicit drugs within 30 days prior to study entry.
• •NSAID use during the pre-procedural period (one week before Treatment Day 0).
• •Preoperative hematocrit less than 36%.
• •History of hemodynamic instability or inability to maintain stable oncotic pressure.
• •History of prolonged clotting times.
• •Prior history of lumbar procedure.
• •Redness, swelling, rash or other concerning lesions at the injection site just prior to the procedure.
• •Prior history of allergy to lidocaine or other local anesthetic agent.